Role of a new polyomavirus in Merkel cell carcinoma

一种新的多瘤病毒在默克尔细胞癌中的作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): We have recently discovered a new human polyomavirus monoclonally-integrated into human Merkel cell carcinomas (MCC) that we call Merkel cell polyomavirus (MCPyV). MCC is a rare neuroectodermal cancer suspected to be caused by a viral infection because of its unusual epidemiology. It is the most aggressive skin cancer and only 50% of patients with advanced disease survive 9 months or longer. MCPyV has a 5.4 kbase genome closely related to murine and African green monkey lymphotropic polyomaviruses (MuPyV and LPyV, respectively). MCPyV is distantly related to SV40 and the four known human polyomaviruses. Human serosurveys show that 15-30% of populations from the US, Japan and Germany have cross-reactive antibodies to LPV which may actually represent reactivity to MCPyV infection. We find similar MCPyV infection rates using direct detection of MCPyV genome from peripheral blood cells. If confirmed, these findings suggest that over a billion persons have been exposed to MCPyV infections worldwide. Southern blotting shows that MCPyV is integrated into MCC genome at different sites in a somatic and monoclonal pattern. One cellular integration site has been defined as the receptor-type protein tyrosine phosphatase-gamma (PTPRG) intron 1. MCPyV also expresses a highly conserved T antigen in tumors. The N-terminus of MCPyV encodes transformation-associated DnaJ and LXCXE pocket protein-binding domains. All tumor- derived MCPyV T antigens, however, possess T antigen mutations that eliminate T antigen origin binding and/or plasmid replication functions. These functions are not needed to maintain integrated virus, suggesting that MCC arises in at least two steps: first, MCPyV integrates into the host genome; second, truncation mutations arise allowing expression of N-terminal transforming domains, but eliminating deleterious C- terminal domains. MCPyV may play a role in tumorigenesis through insertional mutagenesis, expression of T antigen or both. Our proposal seeks to understand these mechanisms for transformation and oncogenesis by 1) identifying additional cell integration sites, 2) analyzing T antigen transforming functions in rodent cells and in cell signaling assays, 3) performing cell-wide proteomic analysis following T antigen expression, 4) identifying novel cellular T antigen direct interactors and 5) generating transgenic mice with MCPyV T antigen expression targeted to Merkel mechanoreceptor cells. Through this systematic approach we anticipate we will learn how this new virus contributes to human carcinogenesis. PUBLIC HEALTH RELEVANCE: This proposal seeks to understand how Merkel cell virus (MCV) contributes to human cancers. MCV has been found as an integrated virus in Merkel cell carcinoma where it expresses T antigen, an oncoprotein that has been well-characterized from closely-related viruses. This proposal will investigate similarities and differences between MCV T antigen and T antigen from other viruses as well as dysregulation of cellular proteins from MCV integration and T antigen expression. Finally, we seek to generate a model system for MCV tumorigenesis that will be useful for drug screening and prevention.
描述(由申请人提供):我们最近发现了一个新的人类多瘤病毒单次融合到人类默克尔细胞癌(MCC)中,我们称之为Merkel细胞多瘤病毒(MCPYV)。 MCC是一种罕见的神经外科癌,涉嫌由于其异常流行病学而引起的病毒感染引起。它是最具侵略性的皮肤癌,只有50%的晚期疾病患者生存9个月或更长时间。 MCPYV的基因组与鼠和非洲绿色猴子淋巴细胞病毒(分别为mupyv和lpyv)密切相关。 MCPYV与SV40和四个已知的人类多瘤病毒遥远相关。人类血清疗法表明,来自美国,日本和德国的人群中有15-30%具有与LPV的交叉反应抗体,这实际上可能代表了对MCPYV感染的反应性。我们发现,使用直接检测到外周血细胞MCPYV基因组的MCPYV感染率相似。如果得到证实,这些发现表明,超过十亿人已经接触到全球MCPYV感染。 Southern印迹表明,MCPYV以体细胞和单克隆模式在不同位置的MCC基因组集成到MCC基因组中。一个细胞整合位点已被定义为受体型蛋白酪氨酸磷酸酶 - γ(PTPRG)内含子1。MCPYV也表达了肿瘤中高度保守的T抗原。 MCPYV的N末端编码与转化相关的DNAJ和LXCXE袖珍蛋白结合结构域。然而,所有肿瘤衍生的MCPYV T抗原均具有T抗原突变,可消除T抗原起源结合和/或质粒复制功能。这些功能不需要维持积分病毒,表明MCC至少在两个步骤中产生:首先,MCPYV集成到宿主基因组中;其次,会出现截短突变,允许表达N末端转化结构域,但消除了有害的c末端结构域。 MCPYV可能通过插入诱变,T抗原或两者的表达在肿瘤发生中起作用。我们的建议试图通过1)确定其他细胞整合位点来理解这些机制,以转化和肿瘤发生,2)分析啮齿动物细胞中的T抗原转化功能和细胞信号测定中的T抗原转化功能,3)3)在T抗原表达中执行细胞范围的蛋白质组学分析,4)与新型细胞T抗原相互作用的靶向Mers Merk and Merk and Mers contertor and Merk and Mcy contrular contigen contertor and Mcy toster contigent and Merk contigent and Merk contigent and Merk contigent and Merk contigent and M. 5)机械感受器细胞。通过这种系统的方法,我们预计我们将学习这种新病毒如何促进人类致癌作用。公共卫生相关性:该提案旨在了解默克尔细胞病毒(MCV)如何对人类癌症做出贡献。 MCV在默克尔细胞癌中被发现为一种综合病毒,在该病毒中,它表达了T抗原,T抗原是一种已从密切相关病毒中充分表征的癌蛋白。该建议将研究其他病毒中MCV T抗原和T抗原之间的相似性和差异,以及MCV整合和T抗原表达的细胞蛋白失调。最后,我们试图为MCV肿瘤发生生成模型系统,该系统对药物筛查和预防非常有用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PATRICK S. MOORE其他文献

PATRICK S. MOORE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PATRICK S. MOORE', 18)}}的其他基金

Discovery and Characterization of New Human Cancer Viruses
新人类癌症病毒的发现和表征
  • 批准号:
    10360576
  • 财政年份:
    2016
  • 资助金额:
    $ 45.51万
  • 项目类别:
Discovery and Characterization of New Human Cancer Viruses
新人类癌症病毒的发现和表征
  • 批准号:
    10115622
  • 财政年份:
    2016
  • 资助金额:
    $ 45.51万
  • 项目类别:
Role of a new polyomavirus in Merkel cell carcinoma
一种新的多瘤病毒在默克尔细胞癌中的作用
  • 批准号:
    8017493
  • 财政年份:
    2009
  • 资助金额:
    $ 45.51万
  • 项目类别:
Role of a new polyomavirus in Merkel cell carcinoma
一种新的多瘤病毒在默克尔细胞癌中的作用
  • 批准号:
    8215839
  • 财政年份:
    2009
  • 资助金额:
    $ 45.51万
  • 项目类别:
Role of a New Polyomavirus in Merkel Cell Carcinoma
新型多瘤病毒在默克尔细胞癌中的作用
  • 批准号:
    8694310
  • 财政年份:
    2009
  • 资助金额:
    $ 45.51万
  • 项目类别:
Role of a new polyomavirus in Merkel cell carcinoma
一种新的多瘤病毒在默克尔细胞癌中的作用
  • 批准号:
    8433428
  • 财政年份:
    2009
  • 资助金额:
    $ 45.51万
  • 项目类别:
MCC Tumor-Specific Biomarkers: Basis for Rational Therapy of Merkel Cell Carcinom
MCC 肿瘤特异性生物标志物:默克尔细胞癌合理治疗的基础
  • 批准号:
    8370549
  • 财政年份:
    2008
  • 资助金额:
    $ 45.51万
  • 项目类别:
MCC Tumor-Specific Biomarkers: Basis for Rational Therapy of Merkel Cell Carcinom
MCC 肿瘤特异性生物标志物:默克尔细胞癌合理治疗的基础
  • 批准号:
    8676455
  • 财政年份:
    2008
  • 资助金额:
    $ 45.51万
  • 项目类别:
Protein Biomarkers for a New Human Polyomavirus in AIDS-related Malignancies
艾滋病相关恶性肿瘤中新型人类多瘤病毒的蛋白质生物标志物
  • 批准号:
    7691836
  • 财政年份:
    2008
  • 资助金额:
    $ 45.51万
  • 项目类别:
MCC Tumor-Specific Biomarkers: Basis for Rational Therapy of Merkel Cell Carcinom
MCC 肿瘤特异性生物标志物:默克尔细胞癌合理治疗的基础
  • 批准号:
    8520225
  • 财政年份:
    2008
  • 资助金额:
    $ 45.51万
  • 项目类别:

相似国自然基金

抗变构/单体形式的C反应蛋白关键抗原表位199-206抗体在狼疮性肾炎小管间质病变中的作用机制及其靶向治疗研究
  • 批准号:
    82300829
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
靶向CLDN18.2抗体的抗原结合特性对CAR-T抗肿瘤活性的调控机制
  • 批准号:
    82303716
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
靶向诱导抗原特异的TH1-like TFH细胞分化促进新冠特异的中和抗体长效应答及机制研究
  • 批准号:
    92269115
  • 批准年份:
    2022
  • 资助金额:
    80.00 万元
  • 项目类别:
    重大研究计划
靶向乙肝表面抗原的单链抗体及其衍生物抑制乙肝病毒和亚病毒颗粒分泌及其机制研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    58 万元
  • 项目类别:
    面上项目
基于抗体的新型抗原靶向肽及其药物偶联物的构建、抗肿瘤活性及作用机制研究
  • 批准号:
    82173674
  • 批准年份:
    2021
  • 资助金额:
    55.00 万元
  • 项目类别:
    面上项目

相似海外基金

Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
个性化疫苗免疫疗法联合检查点抑制剂治疗三阴性乳腺癌的临床评价
  • 批准号:
    10489848
  • 财政年份:
    2021
  • 资助金额:
    $ 45.51万
  • 项目类别:
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
个性化疫苗免疫疗法联合检查点抑制剂治疗三阴性乳腺癌的临床评价
  • 批准号:
    10687287
  • 财政年份:
    2021
  • 资助金额:
    $ 45.51万
  • 项目类别:
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
个性化疫苗免疫疗法联合检查点抑制剂治疗三阴性乳腺癌的临床评价
  • 批准号:
    10254572
  • 财政年份:
    2021
  • 资助金额:
    $ 45.51万
  • 项目类别:
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture
在连续培养中通过减少基因组大肠杆菌生产抗体治疗片段
  • 批准号:
    10081714
  • 财政年份:
    2020
  • 资助金额:
    $ 45.51万
  • 项目类别:
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture
在连续培养中通过减少基因组大肠杆菌生产抗体治疗片段
  • 批准号:
    10215525
  • 财政年份:
    2020
  • 资助金额:
    $ 45.51万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了